Compare American International Group Inc (AIG) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American International Group Inc vs Ascendis Pharma A/S — how do they compare? American International Group Inc trades at $80.51 (market cap $42.98B), while Ascendis Pharma A/S trades at $274.27 (market cap $17.51B). The key difference: American International Group Inc is far larger — about 2.5× Ascendis Pharma A/S's market cap, and American International Group Inc pays a 2.47% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| AIG | ASND | |
|---|---|---|
Market Cap | $42.98B | $17.51B |
Sector | Financials | Health |
52-Week High | $86.59 | $274.50 |
52-Week Low | $71.89 | $163.32 |
Enterprise Value | $50.68B | $17.88B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $81.06, up 2.1% today, showing strong momentum with three consecutive quarterly earnings beats. The stock is supported by bullish technical signals and a consensus price target of $88.13. Recent executive appointments and the acquisition of Everest Colombia signal strategic growth initiatives. Revenue stabilized around $26.8B in 2025 with net income margin improving to 11.88%.
Outlook remains positive with earnings growth and expansion in Latin America offering upside potential. Risks include catastrophe exposure and competitive pressures. Analysts are predominantly neutral with 58.5% Hold ratings, suggesting cautious optimism amid solid fundamentals.
Ascendis Pharma (ASND) trades at $266.97, down 2.74% on the day. The stock maintains a bullish technical outlook with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, revenue growth is strong, reaching $720.13M in 2025, but the company remains unprofitable with a net loss of $228.03M. Recent positive clinical trial data for TransCon CNP and inclusion in Russell indexes highlight ongoing business momentum.
The outlook is optimistic, driven by analyst consensus and a $320 price target, but risks include persistent losses, high debt levels, and reliance on pipeline success. Near-term performance hinges on Q2 2026 earnings versus the $1.29 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
